• 1
    Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction 2010; 105: 21623.
  • 2
    Choopanya K., Des Jarlais D. C., Vanichseni S., Kitayaporn D., Mock P. A., Raktham S. et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr 2002; 29: 8694.
  • 3
    Milloy M. J., Wood E., Small W., Tyndall M., Lai C., Montaner J. et al. Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev 2008; 27: 6939.
  • 4
    Rich J., Dickinson B., Macalino G., Flanigan T. P., Towe C. W., Spaulding A. et al. Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 22: 1616.
  • 5
    Jurgens R., Ball A., Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 2009; 9: 5766.
  • 6
    Marushak L., Beavers R. HIV in Prisons, 2007–2008. Bureau of Justice Statistics. US Department of Justice. Washington, D.C.: Office of Justice Program; 2009. Available from: (accessed 20 December 2009).
  • 7
    Peters R. H., Greenbaum P. E., Edens J. F., Carter C. R., Ortiz M. M. Prevalence of DSM-IV substance abuse and dependence disorders among prison inmates. Am J Drug Alcohol Abuse 1998; 24: 57387.
  • 8
    World Health Organization, United Nations Office On Drugs and Crime & and the Joint United Nations Programme on HIV/AIDS. Joint Position Paper on Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention. Geneva: WHO; 2004.
  • 9
    Chandler R. K., Fletcher B. W., Volkow N. D. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009; 301: 18390.
  • 10
    Kushel M. B., Hahn J. A., Evans J. L., Bangsberg D. R., Moss A. R. Revolving doors: imprisonment among the homeless and marginally housed population. Am J Public Health 2005; 95: 174752.
  • 11
    Binswanger I. A., Stern M. F., Deyo R. A., Heagerty P. J., Cheadle A., Elmore J. G. et al. Release from prison—a high risk of death for former inmates. N Engl J Med 2007; 356: 15765.
  • 12
    Baillargeon J., Giordano T. P., Rich J. D., Wu Z. H., Wells K., Pollock B. H. et al. Accessing antiretroviral therapy following release from prison. JAMA 2009; 301: 84857.
  • 13
    Springer S. A., Pesanti E., Hodges J., Macura T., Doros G., Altice F. L. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 2004; 38: 175460.
  • 14
    Stephenson B. L., Wohl D. A., McKaig R., Golin C. E., Shain L., Adamian M. et al. Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS 2006; 17: 1038.
  • 15
    Springer S. A., Bruce R. D. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manage 2008; 4: 816.
  • 16
    Levasseur L., Marzo J., Ross N., Blatier C. Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis. Annal Med Interne (Paris) 2002; 153(3 Suppl): 1S1419.
  • 17
    Garcia C., Correa G., Hernandez-Viver A., Kinlock T. W., Gordon M. S., Avila C. A. et al. Buprenorphine–naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addict Med 2007; 1: 12632.
  • 18
    Kinlock T. W., Gordon M. S., Schwartz R. P., O'Grady K. E. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav 2008; 35: 3447.
  • 19
    International Harm Reduction Development Program (IHRD) of the Open Society Institute (OSI). Barriers to access: medication-assisted treatment and injection-driven HIV epidemics. In: Open Society Institute (OSI), editor. New York, NY: Open Society Institute; 2008, pp. 15. Available at: (accessed).